XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) today announced that its lead drug candidate hCDR1 has been granted a patent by the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE